Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and...

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors are effective for non-small cell lung cancer (NSCLC) with EGFR mutations.
• Acquired resistance to EGFR inhibitors is a significant clinical challenge.
• Combination therapy is a promising strategy to overcome treatment resistance.

Purpose of the Study:

• To review the rationalities and controversies in translating preclinical combination therapy findings to clinical practice for NSCLC.
• To identify challenges and future directions for combination therapeutic options in NSCLC.

Main Methods:

• Literature review of preclinical (in vitro and in vivo) and clinical studies.
• Analysis of combination strategies including EGFR-tyrosine kinase inhibitors (TKi) with radiotherapy, chemotherapy, targeted therapy, and immunotherapy.

Main Results:

• Preclinical studies demonstrate synergism for various combination therapies.
• Clinical studies investigate the feasibility of combining EGFR-TKi with other treatments.
• A significant gap exists between preclinical data and clinical applicability.

Conclusions:

• Combination therapies offer potential to overcome EGFR inhibitor resistance in NSCLC.
• Translating preclinical success to clinical practice requires addressing identified challenges.
• Future research should focus on optimizing combination strategies for improved NSCLC treatment outcomes.